newsfilter
← Latest News
Business Wire·

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®

GH

Blood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEXEOS® (zongertinib tablets) Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today